Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Review

    Effect of Homoharringtonine as a Combined Regimen for Acute Myeloid Leukemia

    Abinaya Muralidharan1, J. Julius Xavier Scott2, Leena Dennis Joseph3, Srikanth Jeyabalan1★★ Corresponding author

    1. 1Department of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India.
    2. 2Departments of Pediatric Medicine, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India.
    3. 3Departments of Pathology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India.

    CORRESPONDENCE

    Srikanth Jeyabalan

    Department of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Porur, Chennai, Tamil Nadu, India.

    srikanth.j@sriramachandra.edu.in

    Received: 13-05-2021; Revised: 02-08-2021; Accepted: 16-08-2021.

    Volume 12, Issue 3 · pp. 110–114 · PUBLISHED 25 November 2021 · DOI: 10.4103/jpp.jpp_52_21

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Homoharringtonine (HHT), a cephalotaxus alkaloid has shown promising results in the treatment of several hematological disorders such as chronic myeloid leukemia, acute myeloid leukemia (AML), and myelodysplastic syndrome. It is known for its unique mechanism of action by which it prevents the initial elongation step of protein biosynthesis. Hence, it is used in hematological malignancies where it synergistically potentiates the action of other drugs and induces apoptosis. The relevant studies published were searched using an electronic database from 2002 to 2019. The articles published in English were only considered. Search engines such as PubMed, MEDLINE, Google Scholar, and Semantic scholar were used. In this review, we have discussed the effect of HHT in combination with other chemotherapeutic agents for AML with or without genetic mutation specification and the future perspective of these regimens. Although standard treatment options exist for most of these diseases, still cure rates are low with reported morbidity and the drug resistance emergence is pervasive. Thus, novel treatment approaches are crucial for better outcome. Alternative regimens together with HHT have not been a standard practice, although they have shown a very good potential in AML patients. Many of the combinations were also proved to be safe and effective with very low toxic potential. All these data outcomes of various combinations under different scenarios exhibit that HHT has promising results in the treatment of AML which may lead to its approval in the upcoming years.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Muralidharan, A., Scott, J. J. X., Joseph, L. D., & Jeyabalan, S. (2021). Effect of Homoharringtonine as a Combined Regimen for Acute Myeloid Leukemia. Journal of Pharmacology and Pharmacotherapeutics, 12(3), 110–114. https://doi.org/10.4103/jpp.jpp_52_21